This publication summarizes the Pneumococcal Conjugate Vaccine (PCV) strategic demand forecasting completed in the fourth quarter of 2017. The forecast considers all AMC-eligible demand from countries that introduce with Gavi support, countries that transition to fully self-financing following Gavi support, and countries that introduce independent of Gavi support.

The forecasted demand assumes a 3-dose course administered through routine immunization programmes. The demand incorporates volumes for buffer stocks and wastage.

Changes versus the forecast published in May 2017 ("version 2017Q1"), include the following:

- The current point estimate uses a more gradual assumption for India reaching national scale, resulting in overall lower volumes for 2021-2027; however, multiple scenarios continue to exist for India’s expansion and a full Strategic Demand Scenarios update would reflect a range of scenarios for India scale-up overlapping with prior estimates
- With the exception of India, there is no significant change in this forecast compared to the last publication.

Disclaimer: Except for countries which have already applied to Gavi for support for introduction of Pneumococcal Vaccines or are in the process of doing so, this forecast reflects the best possible estimates on countries’ expected time of introduction. The forecasted timeline for future introductions is not subject to approval by country representatives and, as such, does not constitute any commitment or obligation for any of the countries.
Forecasted Demand by Gavi Support Status for the 73 AMC-eligible Countries

Forecasted Demand and Contracted Volumes for 73 AMC-eligible Countries


For information related to the AMC: amc@gavi.org
For information related to the Pneumococcal Conjugate Vaccine Forecast: forecast@gavi.org